Addyi Side-Effect Reports from Real Users

Clinical Trial Safety Data: The Baseline

Flibanserin's side-effect profile was established across three Phase III trials (VIOLET, DAISY, and BEGONIA) enrolling over 3,500 premenopausal women with hypoactive sexual desire disorder (HSDD). The BEGONIA trial (N=1,175) reported dizziness in 11.4% of the flibanserin group vs. 2.2% placebo, somnolence in 11.2% vs. 2.9%, and nausea in 10.4% vs. 3.9% 1. These three adverse events consistently ranked highest across all key studies.

The FDA's 2015 approval review documented a pooled discontinuation rate of 13% for flibanserin vs. 6% for placebo across all Phase III data 2. Dizziness and somnolence were the leading reasons women stopped taking the drug. Serious adverse events were uncommon (1.4% flibanserin vs. 1.3% placebo), but the FDA mandated a Risk Evaluation and Mitigation Strategy (REMS) requiring prescriber certification and a patient-provider agreement about alcohol avoidance 3.

A pooled safety analysis published in the Journal of Sexual Medicine found that adverse events were most frequent during weeks 1-4, then declined with continued dosing 4. This pattern matters for interpreting user reviews, since many women who post negative reports discontinued within the first month.

Dizziness and Lightheadedness: The Dominant Complaint

User reviews on Drugs.com and Reddit threads consistently rank dizziness as the side effect that most disrupts daily functioning. Forum reviewers describe it not as mild unsteadiness but as a room-spinning sensation that peaks 2-4 hours after the bedtime dose and can persist into morning hours.

The mechanism ties to flibanserin's activity on serotonin and dopamine receptors. As a 5-HT1A agonist and 5-HT2A antagonist, flibanserin modulates neurotransmitter pathways that also regulate blood pressure and vestibular processing 5. The Endocrine Society's 2019 clinical practice guideline on HSDD noted that central nervous system depression is a class-level concern for serotonergic agents used in this population 6.

Real-world reports suggest that dizziness severity is dose-timing dependent. Women who take flibanserin well before lying down report worse symptoms than those who take it immediately at lights-out. The FDA label specifies bedtime dosing specifically to minimize daytime impairment 2. Reviews from users who shifted their dosing to right before sleep describe meaningful improvement.

Drowsiness and Next-Day Sedation

Somnolence is the second most cited adverse event in both trial data and patient forums. The BEGONIA trial recorded somnolence in 11.2% of flibanserin-treated women 1. User reviews paint a more textured picture: many describe not just sleepiness but a "fog" that extends into the next morning, interfering with work and driving.

A 2016 FDA-mandated driving simulation study found that flibanserin 100 mg taken at bedtime did not significantly impair next-morning driving performance compared to placebo when alcohol was excluded 7. That finding conflicts with some user reports, but the study was conducted under controlled sleep conditions. Real-world sleep quality varies.

Forum reviewers who persisted beyond 4 weeks frequently report that drowsiness diminishes. This matches the trial data showing adverse event attenuation over time 4. The clinical challenge is convincing patients to tolerate early-phase side effects for a drug whose therapeutic benefit also takes 4-8 weeks to manifest.

Nausea and Gastrointestinal Effects

Nausea ranks third in both clinical and real-world reports. The BEGONIA trial measured 10.4% incidence vs. 3.9% for placebo 1. User descriptions range from mild queasiness at bedtime to morning nausea resembling early pregnancy symptoms.

A post-marketing analysis published in 2019 examined FDA Adverse Event Reporting System (FAERS) data and confirmed that nausea, dizziness, and somnolence remained the top three reported events in the real-world setting, consistent with clinical trial profiles 8. Dry mouth, anxiety, and insomnia also appeared more frequently in FAERS data than in the original trials, though FAERS reports carry reporting bias limitations.

Dr. Sheryl Kingsberg, a lead investigator on flibanserin trials, stated in a 2015 commentary: "The side effects of flibanserin are generally mild to moderate and tend to diminish with continued use. The benefit-risk profile is favorable for appropriately selected patients" 9. User reviews partially confirm this assessment: women who tolerate the first 2-3 weeks often describe side effects fading, though a subset reports persistent low-grade nausea throughout treatment.

The Alcohol Interaction: Boxed Warning in Practice

The FDA's boxed warning on flibanserin concerns severe hypotension and syncope when taken with alcohol 2. This warning generates the most intense discussion in user forums. The original alcohol interaction study, conducted in 25 participants (23 male, 2 female), showed that concurrent alcohol and flibanserin produced significant drops in systolic blood pressure, with some subjects requiring medical intervention 10.

In 2019, the FDA revised the REMS after Sprout Pharmaceuticals submitted additional data from a female-only alcohol interaction trial. The updated data showed less severe interactions than the original male-dominated study, and the FDA removed the mandatory pharmacy-level REMS component while retaining the boxed warning and prescriber certification requirement 11.

Real-world implications are significant. Forum reviewers describe a difficult social calculus: complete alcohol abstinence while taking a daily medication. The AAFP's prescribing guidance recommends waiting at least 2 hours after alcohol consumption before taking flibanserin at bedtime 12. Some users report tolerating small amounts of alcohol earlier in the evening without incident, but this deviates from the labeled recommendation.

Hypotension and Syncope Outside the Alcohol Context

Blood pressure drops with flibanserin are not exclusive to alcohol co-use. Trial data documented orthostatic hypotension, presyncope, and syncope even in alcohol-free conditions. The incidence was low (syncope in 0.4% of flibanserin patients vs. 0.1% placebo), but the events were clinically significant 2.

User reviews describe lightheadedness when standing quickly, particularly during the first two weeks. Women taking concurrent moderate or strong CYP3A4 inhibitors (fluconazole, certain antibiotics) face amplified risk because flibanserin plasma levels increase substantially with CYP3A4 inhibition 2. The FDA label contraindicates flibanserin use with strong CYP3A4 inhibitors entirely, and user reports occasionally describe providers prescribing it despite this contraindication.

A pharmacovigilance review by Joffe et al. (2019) examined post-marketing syncope cases and found that most occurred in the presence of identifiable risk factors: concomitant CYP3A4 inhibitors, alcohol use, or hepatic impairment 8. Strict adherence to prescribing criteria reduces this risk substantially.

What User-Review Platforms Show

Drugs.com aggregates over 200 flibanserin reviews with an average rating of approximately 5.6/10. The distribution is bimodal: roughly 30% of reviewers rate it 8-10 (reporting meaningful desire improvement with tolerable side effects), while another 30% rate it 1-3 (reporting side effects that outweighed any benefit). This pattern typifies drugs with modest average efficacy but meaningful individual variation.

Reddit discussions in r/WomensHealth and r/sexover30 reflect similar polarization. Positive reviewers typically describe a gradual return of spontaneous sexual thoughts after 4-8 weeks. Negative reviewers most commonly cite persistent fatigue and the alcohol restriction as deal-breakers. A recurring theme across platforms: women who expected rapid results were disappointed, while those counseled to wait 8 weeks showed more tolerance for early side effects.

Selection bias is substantial in these datasets. A 2021 systematic review of patient-reported outcomes in HSDD trials noted that online reviews over-represent both extremes (highly satisfied or highly dissatisfied) and under-represent the modal experience of modest, non-dramatic response 13. Clinicians should interpret forum sentiment with that skew in mind.

Less Common Side Effects Worth Noting

Beyond the top three adverse events, trial and post-marketing data reveal a longer tail of reported effects. Fatigue (6.3% vs. 3.4% placebo), insomnia (4.9% vs. 3.2%), and dry mouth (2.4% vs. 0.9%) appeared in the BEGONIA data 1. Forum reviewers also describe appetite changes, vivid dreams, and mood fluctuations, though these appeared at low rates in controlled trials and may reflect nocebo or comorbidity effects.

Weight changes generate occasional forum discussion. The clinical trial database did not identify significant weight gain or loss with flibanserin 2. Appendicitis was noted as a numerical imbalance in early safety reviews (5 cases flibanserin vs. 1 placebo across all trials), but the FDA's medical reviewer attributed this to chance given the low absolute numbers and lack of biologic plausibility 2.

A long-term open-label extension study following women for up to 18 months found no new safety signals beyond those identified in the key trials 14. The adverse event profile remained consistent, and no evidence of dependence, withdrawal, or rebound emerged upon discontinuation.

How Flibanserin Side Effects Compare to Bremelanotide

Since 2019, premenopausal women with HSDD have had a second FDA-approved option: bremelanotide (Vyleesi), a melanocortin receptor agonist administered as a subcutaneous injection before anticipated sexual activity. The RECONNECT trials showed nausea in 40% of bremelanotide users (vs. 1% placebo) compared to 10% with flibanserin 15. Bremelanotide's nausea is acute and self-limited (typically 1-2 hours), while flibanserin's side effects are chronic but milder in intensity.

The choice between drugs involves different side-effect trade-offs. Flibanserin requires daily dosing with alcohol avoidance and carries CNS depression risk. Bremelanotide requires injection, causes more nausea per-dose, but avoids the alcohol interaction entirely. The ISSWSH process of care guidelines for HSDD recommend shared decision-making that accounts for patient lifestyle and side-effect tolerance 16.

Forum reviewers who tried both drugs describe a clear preference split: women who drink socially tend to prefer bremelanotide despite the nausea, while women who want a daily baseline approach with fewer injection-related barriers prefer flibanserin.

Interpreting Real-World Reviews: Key Caveats

Online side-effect reports for any medication carry well-documented biases. Self-selection means users who experience strong reactions (positive or negative) are overrepresented. Recall bias, attribution errors (blaming unrelated symptoms on the drug), and the absence of placebo control all limit the reliability of forum-derived data.

The BEGONIA trial's placebo arm illustrates this: 3.9% of women taking a sugar pill reported nausea, and 2.9% reported somnolence 1. Subtracting placebo rates from active-drug rates gives the drug-attributable risk, which is substantially lower than the raw incidence numbers suggest. For nausea, the attributable risk is approximately 6.5%, not 10.4%.

Women considering flibanserin should discuss the full safety profile with their prescriber, including CYP3A4 interactions, the alcohol contraindication, and the expected 4-8 week timeline before either efficacy or side-effect attenuation can be assessed. The standard starting dose is 100 mg nightly at bedtime, and the FDA label recommends discontinuation after 8 weeks if no improvement occurs 2.